"地方独立行政法人東京都健康長寿医療センターは、東京都板橋区にある地方独立行政法人。1872年に設立された養育院を前身とする、高齢者医学・医療あるいは老年学のリーデイングホスピタル・インスティチュートで、病院と研究所を擁する。理事長は鳥羽研二、センター長は許俊鋭。"

During the past decade, Tokyo Metropolitan Geriatric Hospital conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Metropolitan Geriatric Hospital" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Bayer" with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored, "Kyoto University" with 1 trials sponsored and "Sumitomo Pharma Co., Ltd." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Metropolitan Geriatric Hospital" #1 collaborator was "Asakayama Hospital" with 1 trials as a collaborator, "Cambridge University Hospitals NHS Foundation Trust" with 1 trials as a collaborator, "Kawasaki Medical School Hospital" with 1 trials as a collaborator, "Mie University" with 1 trials as a collaborator and "Nagoya City University Hospital" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Metropolitan Geriatric Hospital" are "Alzheimer Disease" (2 trials), "Alzheimer's Disease" (2 trials), "Cancer" (1 trials), "Cognitive Dysfunction" (1 trials) and "Dementia" (1 trials). Many other conditions were trialed in "Tokyo Metropolitan Geriatric Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Metropolitan Geriatric Hospital" are "Drug" (8 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Crenezumab" (2 trials), "Bromocriptine" (1 trials), "DSP-7888" (1 trials) and "Darolutamide (Nubeqa, BAY1841788)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Metropolitan Geriatric Hospital" are 7 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tokyo Metropolitan Geriatric Hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Tokyo Metropolitan Geriatric Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Metropolitan Geriatric Hospital, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".